Scientific Vita


Shirin Nkongolo

since 08/2022
Physician in training, Heidelberg University Hospital, Internal Medicine IV: Gastroenterology and Infectious Diseases
2019 - 2022
Postdoctoral Fellow, University Health Network, Toronto Centre for Liver Disease (Gehring; Immunology of Chronic Hepatitis B Research Group)
2016 - 2019
Physician in Training/Clinician-Scientist, Heidelberg University Hospital, Internal Medicine IV: Gastroenterology, Hepatology and Infectious Diseases; and Heidelberg University Hospital, Center for Infectious Diseases, Molecular Virology (S. Urban; Hepatitis B and D Viruses Research Group).
2016 - 2016
Research stay, Institut Pasteur Paris, Département Virologie (Vignuzzi; Group "Rapidly Mutating RNA Viruses")
Kuipery A, Mahamed D, Nkongolo S, D’Angelo JA, Johnson-Valiente A, Mehrotra A, Chapman WC, Horton P, McGilvray I, Janssen HLA, Gehring AJ. (2022) The human male liver is predisposed to inflammation via enhanced myeloid responses to inflammatory triggers. Frontiers in Immunology 13:818612. doi 10.3389/fimmu.2022.818612
Nkongolo S, Mohr I, Wenzel JJ, Khalid D, Mieth M, Mehrabi A, Weiss KH, Schnitzler P. (2022) Hepatitis E seroprevalence, cases and management in a large German centre for liver transplantation. Liver Cancer International 3(2):72/81. doi 10.1002/lci2.48
Lempp FA, Roggenbach I, Nkongolo S, Sakin V, Schlund F, Schnitzler P, Wedemeyer H, Le Gal F, Gordien E, Yurdaydin C, Urban S. (2021) A Rapid Point-of-Care Test for the Serodi- agnosis of Hepatitis Delta Virus Infection. Viruses 13:1371. doi 10.3390/v13122371.
Nkongolo S, Nussbaum L, Lempp FA, Wodrich H, Urban S, Ni Y. (2019) The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA. Antiviral Research 168:146-155. doi 10.1016/j.antiviral.2019.04.009.
Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S. (2014) Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. Journal of Hepatology 60(4):723-731. doi 10.1016/j.jhep.2013.11.022.
Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S. (2014) Hepatitis B and D Viruses Exploit Sodium Tau- rocholate Co-transporting Polypeptide for Species-specific Entry into Hepatocytes. Gastroenterology 146(4):1070-1083. doi 10.1053/j.gastro.2013.12.024.
Nkongolo S, Hollnberger J, Urban S. (2022) Bulevirtide als erster spezifischer Wirkstoff gegen Hepatitis-D-Virusinfektion – Mechanismus und klinische Wirkung Bundesge- sundheitsblatt (Robert-Koch-Institut) 65(2):254-263. doi 10.1007/s00103-022-03486-2.
Tu T, Nkongolo S, Urban S. (2019) Analyse chromosomal integrierter HBV-DNA mit inverse nested PCR. Biospektrum 25(3):282-284. doi 10.1007/s12268-019-1047-5
Nkongolo S, Urban S. (2019) Entry inhibition with myrcludex B: a promising future regimen for chronic Hepatitis D Virus infection. In: Hepatitis D – Virology, management and methodology. Herausgegeben von Rizzetto M und Smedile A. Verlag: Il Pensiero Scientifico Editore.
Nkongolo S. (2014) Hepatitis B and D Virus Entry-Inhibitory Activity of Cyclosporin A. Verfügbar bei der Deutschen Nationalbibliothek. doi 10.11588/heidok.00020081
Molecular Virology, Translational Virology
Heidelberg University Hospital
Im Neuenheimer Feld 344
69120 Heidelberg
06221 56 310229